New discoveries for an old drug: a review of recent olanzapine research

  title={New discoveries for an old drug: a review of recent olanzapine research},
  author={Amir M. Meftah and Elizabeth Deckler and Leslie Citrome and Joshua T. Kantrowitz},
  journal={Postgraduate Medicine},
  pages={80 - 90}
ABSTRACT Objective: Based on a substantial literature, olanzapine appears to be one of the most efficacious antipsychotics marketed in the United States, with only clozapine clearly more advantageous. However, olanzapine is marred by an equally substantial literature demonstrating a metabolic burden of olanzapine, particularly for weight gain. With the publication of successful strategies to limit olanzapine induced weight gain, a reassessment of the clinical utility of olanzapine appears… 

Olanzapine/Samidorphan: A New Option for the Treatment of Adults With Schizophrenia or Bipolar I Disorder

The new combination treatment of OLZ/SAM is a unique antipsychotic formulation to provide the recognized efficacious treatment ofOLZ, while mitigating the weight gain and possibly the weight-related adverse effects secondary to OLZ monotherapy.

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder

Clinical trial results support the use of OLZ/SAM as a new treatment option for patients with schizophrenia or BD-I and safety and tolerability findings from clinical studies indicate a similar safety profile to that of olanzapine, with the exception of less weight gain.

Olanzapine-samidorphan combination for schizophrenia or bipolar I disorder

  • L. Citrome
  • Medicine, Psychology
    Current Psychiatry
  • 2022
OSC offers the potential to consider olanzapine earlier in the treatment of schizophrenia or bipolar I disorder, especially among practitioners who might otherwise be hesitant to prescribe this agent because of concerns over the risk of excessive weight gain.

NDT_A_313840 2885..2904

Clinical trial results from more than 1600 subjects support the use of OLZ/SAM as a new treatment option for patients with schizophrenia or BD-I, and safety and tolerability findings from clinical studies indicate a similar safety profile to that of olanzapine.

Comparative, Single-Dose, 2-Way Cross-Over Bioavailability Study of Two Olanzapine 10 Mg Tablet Formulations in Healthy Volunteers Under Fasting Conditions

The generic Olanzapine was bioequivalent to the reference formulation and was well tolerated and provides an acceptable alternative to theReference drug.

Olanzapine-Associated Rhabdomyolysis: A Case Report

The presented case demonstrates that pharmacogenetic‐guided personalization of treatment may allow selecting the best medication and determining the right dosage, resulting in the reduced risk of adverse drug reactions and pharmacoresistance.

Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions

If trials of TAAR-1 modulators, and other novel-mechanism targets for schizophrenia that are under active study, continue to show positive results, the definition of an antipsychotic may need to be expanded beyond the D2R target in the near future.

Agitation in schizophrenia: origins and evidence-based treatment

  • L. Citrome
  • Medicine, Psychology
    Current opinion in psychiatry
  • 2020
Comorbidities can contribute to agitation and can make an accurate differential diagnosis challenging, and the ongoing development of rapidly acting novel formulations of antiagitation medications, if successful, may facilitate clinical treatment by providing additional options.



Olanzapine: review of safety 2008

Olanzapine has a favorable profile in terms of extra-pyramidal side effects and is also relatively prolactin-sparing, and the effectiveness benefits may outweigh the risks, particularly in patients with low baseline risk for metabolic syndrome but monitoring for untoward metabolic effects is crucial.

Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?

Dosing of olanzapine in clinical practice is higher than what has been established in the registration program for schizophrenia or bipolar disorder, and this is somewhat supported by double-blind, controlled clinical trial evidence.

Olanzapine pamoate for the treatment of schizophrenia – a safety evaluation

The safety profile of OLAI was similar to the well-known safety profiles of oral olanzapine, except for the risk of occurrence of post-injection delirium/sedation syndrome (PDSS).

Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.

Existing data suggest that short term modest weight loss is possible with metformin in patients with olanzapine-induced weight gain, and current evidence is insufficient to support any particular pharmacological approach.

Weight gain and antipsychotics: a drug safety review

Recently published data still support the hierarchical ranking of SGAs already proposed in previous reviews, with clozapine and olanzapine as having the highest risk, followed by amisulpride, asenapine, iloperidone, paliperidone and quetiapine in the middle, and aripiprazole, lurasid one and ziprasidone with the lowest risk.

Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.

It is suggested that samidorphan, an opioid antagonist, mitigates weight gain associated with olanzapine, and this study prospectively compared combination therapy of olanZapine plus either samidomorphan or placebo for the treatment of schizophrenia.

Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis

Meta-analytical evidence shows that metformin might decrease weight in children/adolescents treated with SGAs but additional high-quality evidence is needed.

Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses

The results of this study suggest that clozapine is significantly more efficacious than olanzapine in improving positive and negative symptoms in TRS patients.

Use of very-high-dose olanzapine in treatment-resistant schizophrenia